CHOP group achieves temporal control of gene editing with small molecules

As companies home in on ways to temporally control CRISPR/Cas9 gene editing, one academic group thinks small molecule stabilizers could be a solution.

Beverly Davidson, a professor of pathology and laboratory medicine at The Children's Hospital of Philadelphia and co-founder of Spark Therapeutics Inc. (NASDAQ:ONCE), presented data Wednesday at the American Society of Gene and Cell Therapy (ASGCT) meeting showing Cas9 expression and target gene editing can be controlled by fusing a small molecule-regulated kill switch to Cas9...